TNFSF11
Tumor necrosis factor ligand superfamily member 11
As of the edition of 20 October 2026, TNFSF11 (tumor necrosis factor ligand superfamily member 11, UniProt O14788) has 6 drugs tested at it and 5 companies on the list, 0 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- O14788
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Secreted
- Solved structures
- 2
- Disease areas
- Bones, joints and muscles; Nutrition and metabolism; Cancer; Skin and connective tissue; Urinary and reproductive; Injuries; Immune system; Pregnancy and women's health
- Registered trials of its drugs
- 209
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 1 |
| Went quiet | 1 |
| Status not established | 3 |
| Total | 6 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Denosumab | Marketed | Phase 4 | Ended 2022 |
| LY06006 | Status not established | Phase 3 | none listed |
| ENZ215 | Status not established | Phase 3 | none listed |
| LY01011 | Status not established | Phase 3 | none listed |
| MW031 | Went quiet | Phase 3 | none listed |
| MW032 | Active | Phase 3 | none listed |
6 of 6 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 1 |
| Engaged | 2 |
| Undetermined | 2 |
| Total on the list | 5 |
| Company | Route |
|---|---|
| Amgen | Route B |
The other 4 companies at TNFSF11
In the product5 companies in all; 4 are not named here, and no score is.
See the 5 companies at TNFSF11, ranked, with the facts behind eachRequest access. Nothing is shown until you do.